Johnson & Johnson Posts Q4 2025 Revenue Beat, EPS Comes Up Short

Johnson & Johnson (NYSE: JNJ) has announced its financial results for the fourth quarter and the full year of 2025. The company reported a notable increase in revenue, surpassing expectations, while earnings per share slightly missed the mark.

Johnson & Johnson Surpasses Revenue Expectations but Misses EPS Target

Johnson & Johnson reported a revenue of $24.6 billion for the fourth quarter of 2025, exceeding the anticipated $24.15 billion. This represents a 9.1% increase compared to the same period in the previous year. The company’s operational growth stood at 7.1%, with adjusted operational growth at 6.1%. These figures highlight J&J’s ability to leverage its diversified portfolio across its key business segments, including Oncology, Immunology, and Neuroscience.

However, the company’s earnings per share (EPS) for the quarter came in at $2.46, narrowly missing the expected $2.47. This slight shortfall is attributed to the acquisition of Halda Therapeutics, which impacted the EPS by $(0.10). Despite this, the adjusted EPS of $2.46 still marks a significant improvement from the $2.04 reported in the fourth quarter of 2024, showcasing a 20.6% increase.

The company’s performance was further bolstered by its innovative product launches and approvals, such as CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer. These developments have not only expanded J&J’s product offerings but also strengthened its market position in the pharmaceutical sector.

Join our Telegram group and never miss a breaking digital asset story.

Johnson & Johnson’s Optimistic Guidance for 2026

Looking ahead, Johnson & Johnson has issued an optimistic outlook for 2026. The company projects estimated reported sales to reach between $100.0 billion and $101.0 billion, representing a growth rate of 6.2% to 7.2% at the midpoint. This projection underscores J&J’s confidence in its strategic initiatives and its ability to drive sustained growth across its business segments.

The guidance for adjusted EPS is set between $11.43 and $11.63, with a midpoint growth of 6.9% compared to the previous year. This reflects J&J’s focus on enhancing operational efficiency and capitalizing on its robust pipeline of innovative products. The company remains committed to advancing its leadership in key therapeutic areas, such as Oncology and Immunology, while exploring new opportunities in MedTech.

Joaquin Duato, Chairman and CEO of Johnson & Johnson, emphasized the company’s continued focus on medical innovation and strategic investments. He highlighted the role of groundbreaking science and technology in driving J&J’s growth trajectory, paving the way for transformative healthcare solutions that address unmet medical needs. As J&J enters 2026, its strategic priorities and commitment to innovation position it well to achieve its ambitious growth targets.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.